Gatto B, Sanders M M, Yu C, Wu H Y, Makhey D, LaVoie E J, Liu L F
Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
Cancer Res. 1996 Jun 15;56(12):2795-800.
Protoberberine alkaloids (coralyne and its derivatives), which exhibit antileukemic activity in animal models, have been shown to be potent inducers of topoisomerase (topo) I-DNA cleavable complexes using purified recombinant human DNA topo I. Different from the structurally similar benzophenanthridine alkaloid nitidine (a dual poison of both topos I and II), coralyne and its derivatives have marginal poisoning activity against DNA topo II. Yeast cells expressing human DNA topo I are shown to be specifically sensitive to killing by coralyne derivatives and nitidine, suggesting that cellular DNA topo I is their cytotoxic target. Two human camptothecin-resistant cell lines, CPT-K5 and A2780/CPT-2000, which are known to express highly camptothecin-resistant topo I, are only marginally resistant to coralyne derivatives and nitidine. Purification of human topo I from Escherichia coli cells overexpressing CPT-K5 recombinant topo I has demonstrated similar marginal cross-resistance to nitidine. It seems possible to develop coralyne and nitidine derivatives as new topo I-targeted therapeutics to overcome aspects of camptothecin-related resistance.
原小檗碱生物碱(珊瑚碱及其衍生物)在动物模型中表现出抗白血病活性,使用纯化的重组人DNA拓扑异构酶I已证明其是拓扑异构酶(topo)I-DNA可切割复合物的有效诱导剂。与结构相似的苯并菲啶生物碱氧化苦参碱(拓扑异构酶I和II的双重毒药)不同,珊瑚碱及其衍生物对DNA拓扑异构酶II的中毒活性较弱。表达人DNA拓扑异构酶I的酵母细胞显示对珊瑚碱衍生物和氧化苦参碱的杀伤具有特异性敏感性,表明细胞DNA拓扑异构酶I是它们的细胞毒性靶点。两种人喜树碱耐药细胞系CPT-K5和A2780/CPT-2000,已知表达高度耐喜树碱的拓扑异构酶I,对珊瑚碱衍生物和氧化苦参碱仅具有轻微抗性。从过表达CPT-K5重组拓扑异构酶I的大肠杆菌细胞中纯化人拓扑异构酶I已证明对氧化苦参碱具有类似的轻微交叉抗性。开发珊瑚碱和氧化苦参碱衍生物作为新的靶向拓扑异构酶I的治疗药物以克服喜树碱相关抗性的某些方面似乎是可能的。